On November 20, 2024, Reza Zadno, President and Chief Executive Officer of PROCEPT BioRobotics Corp (PRCT, Financial), sold 26,420 shares of the company. Following this transaction, the insider now owns 205,605 shares of the company. The details of this transaction can be found in the SEC Filing.
PROCEPT BioRobotics Corp is a surgical robotics company that develops transformative solutions in urology. The company is known for its innovative technologies that aim to improve patient outcomes and reduce the cost of healthcare.
The insider transaction history for PROCEPT BioRobotics Corp shows that there have been 0 insider buys in total over the past year. Meanwhile, there have been 31 insider sells over the same timeframe. Over the past year, Reza Zadno has sold a total of 355,871 shares and purchased 0 shares.
On the day of the recent sale, shares of PROCEPT BioRobotics Corp were trading at $92.57, giving the stock a market cap of $5,064.345 million. With a price of $92.57 and a GuruFocus Value of $83.42, PROCEPT BioRobotics Corp has a price-to-GF-Value ratio of 1.11, indicating that the stock is modestly overvalued based on its GF Value.
The GF Value is an intrinsic value estimate developed by GuruFocus, calculated based on the following three factors:
- Historical multiples (price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow) that the stock has traded at.
- A GuruFocus adjustment factor based on the company’s past returns and growth.
- Future estimates of business performance from Morningstar analysts.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
